Leonard Zehr, Author at BioTuesdays

Feature

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

As a co-founder, chairman and CEO of Sigyn Therapeutics (pronounced Sig-en) (OTCMarkets:SIGY), a medical device company developing a blood purification system to treat life-threatening inflammatory conditions, including...

August 10, 2021

Feature

Altamira in strategic repositioning to develop RNA therapeutics

Altamira Therapeutics (NASDAQ:CYTO) is using its recent acquisition of closely-held Trasir Therapeutics as a steppingstone for a strategic repositioning to focus on development of RNA therapeutics, while in the medium...

August 3, 2021

Feature

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

With a new, experienced management team and a $47-million series A financing in place, closely-held LENZ Therapeutics is gearing up for a pivotal trial of its aceclidine once-daily eye drop to treat presbyopia, the...

July 27, 2021

Feature

Asensus Surgical building bridge from laparoscopy to robotic surgery

Asensus Surgical (NYSE American:ASXC) is digitizing the interface between surgeons and patients to pioneer a new era of Performance-Guided Surgery with its Senhance Surgical System.

July 20, 2021

Feature

Har Grover talks up GeneTether TNT platform

As CEO of closely-held GeneTether, Har Grover is tackling the emerging potential of gene editing, which has come alive in the past few years. As an entrepreneur, investor, senior executive and strategist with over 30...

July 13, 2021

Feature

Sio Gene Therapies developing CNS-targeted gene therapies

Sio Gene Therapies (NASDAQ:SIOX) is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric...

July 6, 2021

Feature

Seelos Therapeutics addressing unmet needs in CNS disorders

Seelos Therapeutics’ (NASDAQ:SEEL) two late-stage programs are addressing significant unmet needs in CNS disorders, including acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder and...

June 29, 2021

Feature

Arctic Vision sees busy ophthalmic business development in 2021

After closing four licensing deals for five assets in 2020 and so far in 2021, including its latest deal in early June, closely-held Arctic Vision, a leading player in China’s ophthalmology market, has no plans to slow...

June 22, 2021

Feature

CymaBay laser focused on seladelpar pivotal trial for PBC

After resolving a delay in its biliary cholangitis (PBC) program, CymaBay Therapeutics (NASDAQ:CBAY) is activating clinical sites in North America and Europe, and recruiting patients in its global RESPONSE registration...

June 15, 2021

Feature

Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics

Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in order to...

June 8, 2021

Author - Leonard Zehr

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

Altamira in strategic repositioning to develop RNA therapeutics

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

Asensus Surgical building bridge from laparoscopy to robotic surgery

Har Grover talks up GeneTether TNT platform

Sio Gene Therapies developing CNS-targeted gene therapies

Seelos Therapeutics addressing unmet needs in CNS disorders

Arctic Vision sees busy ophthalmic business development in 2021

CymaBay laser focused on seladelpar pivotal trial for PBC

Clene pioneering therapeutic nanocatalysts to improve cellular bioenergetics

General

More